WATCH: Post-grant proceedings in life sciences—strategic offense and defense in the US and Europe

Phil Hirschhorn, Partner at Panitch Law, moderates a discussion with Erin Dunston, Partner at Panitch Schwarze; Mythili Markowski, Patent Attorney at Regeneron; and Victoria Pedanou, Patent Counsel at Sanofi.The panel explores both defensive and offensive post-grant tactics, examining how the post-Allergan landscape affects obviousness-type double patenting and how §101 challenges are increasingly targeting diagnostic and therapeutic methods. They outline how prosecution approaches can be tailored to anticipate these challenges from the outset.Comparing mechanisms across jurisdictions, the session considers the strategic differences between US IPR/PGR proceedings and European opposition and UPC actions. The discussion further highlights correction mechanisms, such as reissue and reexamination, and the critical role technical experts play in securing successful outcomes.